B2M and Miyoshi myopathy: To put into perspective, a patient with R-ISS stage III MM would be characterized by having elevated beta-2-microglobulin of 5.5 mg/dL or higher, the presence of high-risk cytogenetics, and/or elevated lactate dehydrogenase.